High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer
(2017) In PLoS ONE 12(8).- Abstract
Background: High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer (mCRC) as a prognostic factor for overall survival and in relation to benefit of first-line chemotherapy. Methods: Immunohistochemical staining was conducted and evaluated in tumours from 455 mCRC patients. Kaplan-Meier analysis and Cox regression proportional hazards models were used to access the impact of RBM3 expression on overall survival (OS) and progression-free survival (PFS). Results: High RBM3 expression, both nuclear and... (More)
Background: High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer (mCRC) as a prognostic factor for overall survival and in relation to benefit of first-line chemotherapy. Methods: Immunohistochemical staining was conducted and evaluated in tumours from 455 mCRC patients. Kaplan-Meier analysis and Cox regression proportional hazards models were used to access the impact of RBM3 expression on overall survival (OS) and progression-free survival (PFS). Results: High RBM3 expression, both nuclear and cytoplasmic, was an independent prognostic factor for prolonged OS (hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.50–0.90 and HR 0.66, 95% CI 0.48–0.91, respectively). PFS was significantly longer in patients with high RBM3 expression who had received first-line oxaliplatin based treatment, compared to those who had received irinotecan based treatment, both regarding nuclear and cytoplasmic expression (p-value 0.020 and 0.022 respectively). Conclusion: High RBM3 expression is an independent predictor of prolonged survival in mCRC patients, in particular in patients treated with first-line oxaliplatin based chemotherapy.
(Less)
- author
- Siesing, Christina LU ; Sorbye, Halfdan ; Dragomir, Anca ; Pfeiffer, Per ; Qvortrup, Camilla ; Pontén, Fredrik ; Jirström, Karin LU ; Glimelius, Bengt and Eberhard, Jakob LU
- organization
- publishing date
- 2017
- type
- Contribution to journal
- publication status
- published
- subject
- in
- PLoS ONE
- volume
- 12
- issue
- 8
- article number
- e0182512
- publisher
- Public Library of Science (PLoS)
- external identifiers
-
- pmid:28800641
- wos:000407431800019
- scopus:85027283404
- ISSN
- 1932-6203
- DOI
- 10.1371/journal.pone.0182512
- language
- English
- LU publication?
- yes
- id
- 5270ff73-aa1a-42d5-a6b7-c3bcacbfe1f3
- date added to LUP
- 2017-09-04 10:49:02
- date last changed
- 2024-08-19 04:14:25
@article{5270ff73-aa1a-42d5-a6b7-c3bcacbfe1f3, abstract = {{<p>Background: High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer (mCRC) as a prognostic factor for overall survival and in relation to benefit of first-line chemotherapy. Methods: Immunohistochemical staining was conducted and evaluated in tumours from 455 mCRC patients. Kaplan-Meier analysis and Cox regression proportional hazards models were used to access the impact of RBM3 expression on overall survival (OS) and progression-free survival (PFS). Results: High RBM3 expression, both nuclear and cytoplasmic, was an independent prognostic factor for prolonged OS (hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.50–0.90 and HR 0.66, 95% CI 0.48–0.91, respectively). PFS was significantly longer in patients with high RBM3 expression who had received first-line oxaliplatin based treatment, compared to those who had received irinotecan based treatment, both regarding nuclear and cytoplasmic expression (p-value 0.020 and 0.022 respectively). Conclusion: High RBM3 expression is an independent predictor of prolonged survival in mCRC patients, in particular in patients treated with first-line oxaliplatin based chemotherapy.</p>}}, author = {{Siesing, Christina and Sorbye, Halfdan and Dragomir, Anca and Pfeiffer, Per and Qvortrup, Camilla and Pontén, Fredrik and Jirström, Karin and Glimelius, Bengt and Eberhard, Jakob}}, issn = {{1932-6203}}, language = {{eng}}, number = {{8}}, publisher = {{Public Library of Science (PLoS)}}, series = {{PLoS ONE}}, title = {{High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer}}, url = {{http://dx.doi.org/10.1371/journal.pone.0182512}}, doi = {{10.1371/journal.pone.0182512}}, volume = {{12}}, year = {{2017}}, }